The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis

Bone ◽  
2020 ◽  
Vol 136 ◽  
pp. 115336 ◽  
Author(s):  
Andreas Fontalis ◽  
Richard Eastell
Keyword(s):  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Bisphosphonate Treatment ◽  
Treatment Of Osteoporosis ◽  
Turnover Markers

scholarly journals Serumβ-Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Xiao-Juan Xu ◽  
Lin Shen ◽  
Yan-Ping Yang ◽  
Rui Zhu ◽  
Bo Shuai ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Bone Turnover Markers ◽  
Enzyme Linked Immunosorbent Assay ◽  
Functional Communication ◽  
Mineral Density ◽  
Wnt Pathways ◽  
Turnover Markers

Objective. To demonstrate the role of Wnt/β-catenin canonical pathway in postmenopausal osteoporosis by evaluating serumβ-catenin levels in patients with postmenopausal osteoporosis and analyzing their possible relationship with serum OPG, RANKL, the ratio of RANKL/OPG, sclerostin, and bone turnover markers.Methods. 480 patients with postmenopausal osteoporosis and 170 healthy postmenopausal women were enrolled in the study. Serumβ-catenin, OPG, RANKL, and sclerostin levels were measured by enzyme-linked immunosorbent assay. Bone status was assessed by measuring bone mineral density and bone turnover markers. Estradiol levels were also detected.Results. Serumβ-catenin levels were lower in postmenopausal osteoporotic women compared to nonosteoporotic postmenopausal women (26.26±14.81versus39.33±5.47 pg/mL,P<0.001). Serumβ-catenin was positively correlated with osteoprotegerin (r=0.232,P<0.001) and negatively correlated with the ratio of RANKL/OPG, body mass index, and sclerostin (r=-0.128,P=0.005;r=-0.117,P=0.010;r=-0.400,P<0.001, resp.) in patients with postmenopausal osteoporosis.Conclusion. The results indicate that lower serumβ-catenin and concomitantly higher ratio of RANKL/OPG may be involved in the pathogenesis of postmenopausal osteoporosis. Functional communication between RANKL/RANK/OPG system and Wnt pathways plays an important role in postmenopausal osteoporosis.

Decreased Bone Turnover Markers in Children on Long-Term Parenteral Nutrition (PN) for Intestinal Failure (IF)

2013 ◽  
Vol 39 (1) ◽  
pp. 85-94 ◽  
Author(s):  
Charlène Derepas ◽  
Christina Kosar ◽  
Yaron Avitzur ◽  
Paul W. Wales ◽  
Glenda Courtney-Martin
Keyword(s):  
Parenteral Nutrition ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Intestinal Failure ◽  
Turnover Markers

Denosumab in Osteoporosis and Oncology

2009 ◽  
Vol 43 (9) ◽  
pp. 1445-1455 ◽  
Author(s):  
Jill S Burkiewicz ◽  
Sarah L Scarpace ◽  
Susan P Bruce
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Adverse Effects ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Neoplastic Disease ◽  
Mineral Density ◽  
Treatment Of Osteoporosis ◽  
Additional Clinical Trial ◽  
Turnover Markers

Objective: To review the pharmacology, pharmacokinetics, pharmacodynamics, safety, efficacy, and use of denosumab in osteoporosis, breast cancer, prostate cancer, and multiple myeloma. Data Sources: Studies and abstracts were identified through MEDLINE and International Pharmaceutical Abstracts (1966–July 2009). Key search terms include denosumab, AMG-162, and receptor activator of nuclear factor-κB ligand system. Information available in abstract form was retrieved from major oncology and bone metabolism meetings. Additional data were obtained from the manufacturer. Study Selection and Data Extraction: All available studies in humans were included except for studies in rheumatoid arthritis and giant cell tumor of the bone. Data Synthesis: In patients with osteoporosis, denosumab significantly reduces bone resorption and fractures. Studies of denosumab in the prevention and treatment of osteoporosis have demonstrated significantly increased bone mineral density and reduced bone turnover markers. Studies of denosumab versus placebo in the treatment of osteoporosis have demonstrated reductions in vertebral, hip, and nonvertebral fractures. In oncology, positive results from clinical trials in patients receiving endocrine therapy for breast and prostate cancer demonstrated decreases in bone loss and skeletal-related events. Denosumab seems to be at least as effective in reducing bone turnover markers as intravenous bisphosphonates in the oncology setting. The most common adverse effects in patients with osteoporosis were arthralgia, nasopharyngitis, back pain, and headache. The most common adverse effects in patients with cancer were infection, pain in the extremities, arthralgia, bone pain, fatigue, and pain. Serious adverse effects include infections requiring hospitalization. Conclusions: Denosumab has documented efficacy and safety in patients with osteoporosis, breast cancer, and prostate cancer. Additional clinical trial data are needed to more completely establish the effectiveness of denosumab in the treatment of osteoporosis and neoplastic disease as well as its cost-effectiveness and long-term safety.

scholarly journals Obesity and Bone Loss at Menopause: The Role of Sclerostin

Diagnostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1914
Author(s):  
Paolo Marzullo ◽  
Chiara Mele ◽  
Stefania Mai ◽  
Antonio Nardone ◽  
Massimo Scacchi ◽  
...  
Keyword(s):  
Body Composition ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Health ◽  
Bone Turnover Markers ◽  
Turnover Markers ◽  
Total Body

Background. Peripheral fat tissue is known to positively influence bone health. However, evidence exists that the risk of non-vertebral fractures can be increased in postmenopausal women with obesity as compared to healthy controls. The role of sclerostin, the SOST gene protein product, and body composition in this condition is unknown. Methods. We studied 28 severely obese premenopausal (age, 44.7 ± 3.9 years; BMI, 46.0 ± 4.2 kg/m2) and 28 BMI-matched post-menopausal women (age, 55.5 ± 3.8 years; BMI, 46.1 ± 4.8 kg/m2) thorough analysis of bone density (BMD) and body composition by dual X-ray absorptiometry (DXA), bone turnover markers, sclerostin serum concentration, glucose metabolism, and a panel of hormones relating to bone health. Results. Postmenopausal women harbored increased levels of the bone turnover markers CTX and NTX, while sclerostin levels were non-significantly higher as compared to premenopausal women. There were no differences in somatotroph, thyroid and adrenal hormone across menopause. Values of lumbar spine BMD were comparable between groups. By contrast, menopause was associated with lower BMD values at the hip (p < 0.001), femoral neck (p < 0.0001), and total skeleton (p < 0.005). In multivariate regression analysis, sclerostin was the strongest predictor of lumbar spine BMD (p < 0.01), while menopausal status significantly predicted BMD at total hip (p < 0.01), femoral neck (p < 0.001) and total body (p < 0.05). Finally, lean body mass emerged as the strongest predictor of total body BMD (p < 0.01). Conclusions. Our findings suggest a protective effect of obesity on lumbar spine and total body BMD at menopause possibly through mechanisms relating to lean body mass. Given the mild difference in sclerostin levels between pre- and postmenopausal women, its potential actions in obesity require further investigation.

Sign in / Sign up

Export Citation Format

Share Document